COVID-19 & Psoriasis Resource Center

To assist dermatologists and the patients they serve, the IPC is collecting information from around the world on coronavirus and psoriasis. If you have a resource on COVID-19 and psoriasis to add, please submit it to IPC.

Latest news on COVID-19 & Psoriasis

Update on PsoProtect Registry Data

March 17, 2021

Commentary: Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19.

February 08, 2021

Commentary: Cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion

February 02, 2021

Commentary: NPF COVID-19 Task Force Guidance Statements

January 06, 2021

IPC Statement on COVID-19 & PsoriasisIPC's statement provides general guidance to physicians treating psoriasis patients based on the current understanding of the impact of COVID-19 and psoriasis.

Expert Opinions

Hear from world psoriasis experts their take on the most current publications on COVID-19.

Stories from the Field View videos and read interviews from some of IPC's experts regarding the impact on psoriasis care during the COVID-19 pandemic.

Treatment GuidelinesView recommendations from professional and patient societies around the globe that have provided additional information regarding treating patients with psoriasis during the COVID-19 pandemic.

PsoProtect Registry

Help us learn more about the impact on psoriasis and COVID-19 by participating in this global registry. You can submit a case on-line.

Key Publications Review articles on COVID-19 selected by IPC's Chief Medical Officer.

IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT

The National Psoriasis Foundation
COVID-19 Task Force Guidance Statements

Twenty-five key recommendations for the management of patients with psoriatic disease during the COVID-19 pandemic.

READ STATEMENTS

THIS WEEKS' PUBLICATIONS ON COVID-19 & PSORIASIS

Psoriasis, COVID-19 and shielding
No abstract

Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID-19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin
The global pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging. Various cutaneous manifestations have been observed in patients with SARS-CoV-2 infection, yet exacerbations of psoriasis have been reported sporadically. Acrodermatitis continua of Hallopeau (ACH) is an uncommon, sterile pustular dermatosis involving one or more digits. In some rare cases, ACH may evolve into generalized pustular psoriasis...

Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic
No abstract

Incidence and prognosis of COVID-19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study
No abstract

Psoriasis care during the time of COVID-19: real-world data on changes in treatments and appointments from a German university hospital
CONCLUSION: It is particularly crucial to tailor psoriasis care to individual needs in order to protect the physical and mental well-being of patients during the pandemic.

VIEW ALL ON PUBMED

RECOURCES FROM OUR INDUSTRY PARTNERS

AbbVie
Amgen
Novartis
UCB